This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
by Zacks Equity Research
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
BMYNegative Net Change EXELNegative Net Change KRYSPositive Net Change TRDAPositive Net Change
biotechnology biotechs pharmaceuticals
Bristol Myers (BMY) Gains 16% in a Month: Should You Buy or Wait?
by Ekta Bagri
Bristol Myers' (BMY) impressive second-quarter results propelled the stock in the past month. However, we advise investors not to be over-optimistic at this point and look before they leap.
BMYNegative Net Change PFEPositive Net Change GILDNegative Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
by Zacks Equity Research
Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.
MRKPositive Net Change ELANPositive Net Change FULCPositive Net Change TRDAPositive Net Change
biotechs medical pharmaceuticals
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
by Zacks Equity Research
Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.
PCRXPositive Net Change FULCPositive Net Change IMTXPositive Net Change TRDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
by Zacks Equity Research
Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.
INSMNegative Net Change FULCPositive Net Change IMTXPositive Net Change TRDAPositive Net Change
biotechs earnings medical
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.
REGNNegative Net Change NTLAPositive Net Change FULCPositive Net Change TRDAPositive Net Change
biotechs earnings
Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
by Zacks Equity Research
Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.
SNYPositive Net Change NVAXPositive Net Change FULCPositive Net Change TRDAPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
by Zacks Equity Research
Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.
FOLDPositive Net Change ANIXPositive Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
by Zacks Equity Research
Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
NBIXPositive Net Change XENEPositive Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.
GSKPositive Net Change GILDNegative Net Change ANIXPositive Net Change TRDAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
by Zacks Equity Research
Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.
IOVAPositive Net Change FULCPositive Net Change IMTXPositive Net Change TRDAPositive Net Change
biotechs cell-therapy earnings medical
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
by Zacks Equity Research
Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.
RHHBYPositive Net Change BMYNegative Net Change NVOPositive Net Change PRTAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.
EXASPositive Net Change FULCPositive Net Change MIRMPositive Net Change TRDAPositive Net Change
biotechs earnings
SpringWorks (SWTX) Q2 Earnings Beat, Ogsiveo Drives Revenues
by Zacks Equity Research
SpringWorks (SWTX) reports better-than-expected second-quarter results. The newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
EXASPositive Net Change FULCPositive Net Change TRDAPositive Net Change
biotechs earnings
Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
SNYPositive Net Change ANIXPositive Net Change KYMRPositive Net Change TRDAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
ANIXPositive Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
by Zacks Equity Research
Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.
ANIXPositive Net Change AKROPositive Net Change VTRSNegative Net Change TRDAPositive Net Change
biotechs earnings medical pharmaceuticals
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
by Zacks Equity Research
Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.
ALLOPositive Net Change FULCPositive Net Change IMTXPositive Net Change TRDAPositive Net Change
biotechs cell-therapy crispr earnings medical
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Catalyst (CPRX) gains as it reports strong second-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, primarily driven by strong Firdapse sales.
CPRXPositive Net Change ANIXPositive Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
by Zacks Equity Research
Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.
VRTXNegative Net Change EDITPositive Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
by Zacks Equity Research
Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations. Stock falls during after-market trading.
RHHBYPositive Net Change SRPTPositive Net Change IMTXPositive Net Change TRDAPositive Net Change
biotechs earnings gene-therapy medical pharmaceuticals
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.
EXELNegative Net Change ANIXPositive Net Change AKROPositive Net Change TRDAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Beam Therapeutics (BEAM) reports mixed second-quarter results. The company remains focused on pipeline development.
BEAMPositive Net Change EXASPositive Net Change FULCPositive Net Change TRDAPositive Net Change
biotechs earnings
Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up
by Zacks Equity Research
Halozyme (HALO) reports better-than-expected second-quarter 2024 results. The company maintains revenue guidance for 2024. Stock rises in after-hours trading.
RHHBYPositive Net Change JNJPositive Net Change HALOPositive Net Change EXASPositive Net Change
biotechs earnings
Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024. Stock falls.
AZNPositive Net Change NVOPositive Net Change LLYPositive Net Change AMGNNegative Net Change
biotechs